203695
bpV(phen)
A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.
别名:
bpV(phen), Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII
登录 查看组织和合同定价。
选择尺寸
关于此项目
Assay:
≥99% (51V-NMR)
Form:
solid
Quality level:
Storage condition:
OK to freeze
protect from light
protect from light
产品名称
bpV(phen), A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.
SMILES string
[V]=O.[K+].n1c2c3ncccc3ccc2ccc1.OO.OO
InChI
1S/C12H8N2.K.2H2O2.O.V/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1;;2*1-2;;/h1-8H;;2*1-2H;;/q;+1;;;;
InChI key
MQPXOTNOFVCXDA-UHFFFAOYSA-N
assay
≥99% (51V-NMR)
form
solid
potency
38 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
yellow
solubility
water: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cell permeable: no
Primary Target
PTEN
PTEN
Product does not compete with ATP.
Reversible: no
Disclaimer
Toxicity: Standard Handling (A)
General description
A potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM).
The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
Other Notes
Schmid, A.C., et al. 2004. FEBS Lett.566, 35.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.
Packaging
Packaged under inert gas
Preparation Note
Unstable in solution; reconstitute just prior to use.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Sameer S Chopra et al.
Cell systems, 10(1), 66-81 (2019-12-10)
Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持